Zevra Therapeutics Hits New 52-Week High, Surging 209% in a Year

Zevra Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 14.53 on June 30, 2026. This achievement underscores the company's impressive performance over the past year, with a remarkable 209.05% increase compared to the S&P 500's 20.86% gain during the same period. The company's financial metrics reflect strong operational health, highlighted by a return on equity (ROE) of 89.05% and a price-to-book ratio of 3.48. Zevra's market capitalization stands at USD 538 million, indicating its position as a small-cap entity within the industry. The company has also demonstrated robust growth, with a staggering 392.61% increase in operating profit and a net profit of USD 52.5 million, which has surged by 227.97%. Zevra Therapeutics has consistently delivered positive results, achieving outstanding performance over the last five consecutive quarters. With high institutional holdings at 82.89%, the company is well-positioned in the market, showcasing its ability to outperform both in the near and long term.